(KPC) transgenic mouse model of pancreatic cancer

Previous work has shown that vitamin E δ-tocotrienol (VEDT) prolongs survival and delays progression of pancreatic cancer in the LSL-Kras;Pdx-1-Cre mouse model of pancreatic cancer. However, the effect of VEDT alone or in combination with gemcitabine in the more aggressive LSL-Kras;LSLTrp53;Pdx-1-Cre (KPC) mouse model is unknown. Here, we studied the effects of VEDT and the combination of VEDT and gemcitabine in the KPC mice. KPC mice were randomized into 4 groups: 1) vehicle (olive oil, 1.0 mL/kg PO twice/day and PBS 1.0 mL/kg IP twice/week), 2) gemcitabine (100 mg/kg IP twice/week), 3) VEDT (200 mg/kg PO twice/day), and 4) gemcitabine + VEDT. Mice received treatment until they displayed symptoms of impending death from pancreatic cancer, at which point animals were euthanized. At 16 weeks, survival was 10% in the vehicle group, 30% in the gemcitabine group, 70% in the VEDT group (P<0.01), and 90% in the VEDT combined with gemcitabine group (P<0.05). VEDT alone and combined with gemcitabine resulted in reversal of epithelial-to-mesenchymal transition in tumors. Biomarkers of apoptosis (plasma CK18), PARP1 cleavage, and Bax expression were more greatly induced in tumors subjected to combined treatment versus individual treatment. Combined treatment induced cell cycle inhibitors (p27 and p21) and inhibited VEGF, vascularity (CD31), and oncogenic signaling (pAKT, pMEK, and pERK) greater than individual drugs. No significant differences in body weight gain between drug treatment and control mice were observed. These results strongly support further investigation of VEDT alone and in combination with gemcitabine for pancreatic cancer prevention and treatment. Cancer Research. on February 6, 2021. © 2013 American Association for cancerpreventionresearch.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on August 20, 2013; DOI: 10.1158/1940-6207.CAPR-13-0157

[1]  M. Metcalfe,et al.  Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[2]  S. Hingorani,et al.  Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. , 2013, Carcinogenesis.

[3]  O. Takeuchi,et al.  Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer , 2013, Clinical & Experimental Metastasis.

[4]  B. Aggarwal,et al.  Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets , 2012, International journal of cancer.

[5]  D. Tu,et al.  Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. , 2012, European journal of cancer.

[6]  S. Sebti,et al.  Vitamin E δ-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer , 2011, Molecular Cancer Therapeutics.

[7]  W. Stone,et al.  Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. , 2011, Free radical biology & medicine.

[8]  G. Feldmann,et al.  Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research , 2011, Expert opinion on drug discovery.

[9]  B. Aggarwal,et al.  Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. , 2010, Biochemical pharmacology.

[10]  B. Aggarwal,et al.  {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. , 2010, Cancer research.

[11]  M. Sporn,et al.  Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer , 2010, Cancer Prevention Research.

[12]  Y. Yap,et al.  Gamma‐tocotrienol as an effective agent in targeting prostate cancer stem cell‐like population , 2010, International journal of cancer.

[13]  A. Radhakrishnan,et al.  Tocotrienols are good adjuvants for developing cancer vaccines , 2010, BMC Cancer.

[14]  K. Nesaretnam,et al.  Tocotrienols Suppress Proinflammatory Markers and Cyclooxygenase-2 Expression in RAW264.7 Macrophages , 2009, Lipids.

[15]  K. Nesaretnam,et al.  Suppression of Tumor Growth by Palm Tocotrienols Via the Attenuation of Angiogenesis , 2009, Nutrition and cancer.

[16]  Y. Yap,et al.  γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways , 2008, British Journal of Cancer.

[17]  S. Tomita,et al.  Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. , 2008, The Journal of nutrition.

[18]  K. Nakagawa,et al.  Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol. , 2008, Biochemical pharmacology.

[19]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[21]  Sanjay Gupta,et al.  Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. , 2006, Biochemical and biophysical research communications.

[22]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[23]  P. Taylor,et al.  Nutritional interventions in cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Kalthoff,et al.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.

[25]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[26]  D. Albanes,et al.  Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. , 1999, Journal of the National Cancer Institute.

[27]  R. Hayes,et al.  Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. , 1998, Journal of the National Cancer Institute.

[28]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[29]  A. Radhakrishnan,et al.  Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells , 2011, Genes & Nutrition.

[30]  B. Aggarwal,et al.  Vitamin E tocotrienols: life beyond tocopherols , 2011, Genes & Nutrition.

[31]  D. Hussein.  d-delta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic tumor cells , 2008 .

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.